Xeris Stock Jumps 25% as Quarterly Revenue Rises 44% and Full-Year Guidance Is Raised

Xeris Biopharma Holdings (Nasdaq: XERS) shares jumped 25.1% on Thursday, Nov. 5, 2026, after the company reported third-quarter results and raised its full-year revenue guidance. The stock closed at $13.08, up from a previous close of $10.46, on volume about 5.9 times normal. The S&P 500 ETF (SPY) fell 4.41% over the same session.

The move followed a press release furnished with an 8-K filed before the market open. The release said total revenue for the third quarter rose 44% from a year earlier to $107.2 million, led by Recorlev, whose net revenue rose 93% to more than $71 million.

Guidance and long-term outlook raised

The company raised its 2026 total revenue guidance to $395 million to $405 million and lifted its 2030 total revenue outlook to more than $1 billion, up from approximately $750 million. Chairman and CEO John Shannon said Recorlev is now on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected.

Profit and margins

Third-quarter net income was $11.3 million, compared with $0.6 million a year earlier. Gross margin improved to 88% from 85%, and adjusted EBITDA was $30.8 million, up $13.3 million. Selling, general and administrative expenses rose 38%, which the company attributed mainly to higher personnel costs tied to the Recorlev commercial expansion.

Pipeline and cash

Xeris said it remains on track to start its pivotal Phase 3 Cornerstone study of XP-8121 by year-end 2026. The company's 2028 convertible notes have been fully retired, eliminating about $34 million of debt. Cash and cash equivalents stood at $131.1 million at September 30, 2026.